UBS Initiates Coverage On Enfusion with Neutral Rating, Announces Price Target of $9
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Kevin Mcveigh has initiated coverage on Enfusion (NYSE:ENFN) with a Neutral rating and a price target of $9.
November 07, 2023 | 1:52 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
UBS has initiated coverage on Enfusion with a Neutral rating and a price target of $9.
The news of UBS initiating coverage on Enfusion with a Neutral rating and a price target of $9 is directly related to Enfusion. This could bring more attention to the stock but the neutral rating suggests that the stock's price may not change significantly in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100